Adjuvant CDK4/6 inhibitors combined with endocrine therapy in HR-positive, HER2-negative early breast cancer: A meta-analysis of randomized clinical trials

BACKGROUND: The benefit of adjuvant cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors with endocrine therapy (ET) in hormone receptor-positive, human epidermal growth factor 2 receptor-negative (HR+/HER2-) early breast cancer (EBC) is uncertain. Hence, we performed a meta-analysis to determine the...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Hong-Fei, Lin, Ying-Yi, Zhu, Teng, Ji, Fei, Zhang, Liu-Lu, Yang, Ci-Qiu, Yang, Mei, Li, Jie-Qing, Cheng, Min-Yi, Wang, Kun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8287214/
https://www.ncbi.nlm.nih.gov/pubmed/34271289
http://dx.doi.org/10.1016/j.breast.2021.07.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8287214/
https://www.ncbi.nlm.nih.gov/pubmed/34271289
http://dx.doi.org/10.1016/j.breast.2021.07.002

Ejemplares similares